Amgen in the news

Ada Visa has joined Amgen as Global Development Scientist Director, bringing her oncology drug development expertise to the team.

Amgen's stock is trending on Zacks.com, but its shares have recently declined, and it holds a Zacks Rank #3 (Hold) based on earnings estimate revisions.

Colton Groome Financial Advisors LLC sold 3,524 Amgen Inc. shares, while Amgen reported strong Q3 earnings, declared a dividend, and saw varied analyst ratings and insider stock sales.

Amgen's stock received a Neutral rating from Cantor Fitzgerald with a USD 400 target, while its Q2 revenue increased by 9.5% to USD 10.05 billion.

Argent Capital Management LLC sold 2,546 shares of Amgen Inc., while other institutional investors made minor adjustments to their holdings, and analysts provided new price targets.

Amgen is focusing on a late-stage obesity drug candidate featuring a once-quarterly dosing, leveraging its biologics expertise amidst a competitive market, and discontinuing an earlier program.

Cantor Fitzgerald reiterated a Neutral rating on Amgen, citing strong commercial execution and a quiet catalyst calendar through year-end 2026, while Amgen also announced successful Phase 3 trial results for dazodalibep in Sjögren’s disease.

Congressman David J. Taylor bought Amgen and Home Depot stocks and sold Marathon Petroleum shares, with each transaction valued between $1,001 and $15,000.

Representative David Taylor purchased Amgen shares between $1,001 and $15,000 on September 22nd, with the company also reporting strong earnings, a dividend, and significant institutional ownership.

Ohio Representative David Taylor bought Amgen stock valued up to $45,000 on September 22, 2026, with Amgen shares currently down 0.76%.

Conor Hughes, a process development associate at Amgen, details his journey into biotech, his role in process development and inspection, and the benefits of Amgen's graduate program.

Amgen achieved a late-stage immunology win with positive data for an autoimmune condition candidate, while also focusing on a lead obesity candidate and benefiting from a broader market rotation towards healthcare.

Amgen is dedicated to advancing the understanding and treatment of discoid lupus erythematosus (DLE), an autoimmune skin condition with limited current therapeutic options.

Amgen's stock dipped 3.38% to $407.27, underperforming market gains, with upcoming earnings projected to show growth.

Amgen Inc. stock fell 3.38% on October 1st due to profit-taking, valuation recalibration, and concerns over pipeline timelines, competitive pressures, and substantial debt.

Amgen is advancing Daxdilimab into Phase III trials for discoid lupus following positive mid-stage results.

Amgen's stock valuation is a subject of debate after positive Phase 3 trial results for its Sjögren's disease drug and concerns about its obesity market strategy.

Amgen's research into a weight-loss drug paradoxically mimics one gut hormone while blocking another, differing from Eli Lilly's successful dual-activation approach.

Amgen's MariTide, a GIP blocker, may achieve similar weight loss outcomes to Lilly's GIP activator Zepbound by ultimately converging on reduced GIP signaling and enhanced GLP-1 effects.

Amgen's daxdilimab antibody showed a 6-point reduction in disease severity for discoid lupus in a phase 2 trial, leading to plans for further development.